The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Eprenetapopt plus venetoclax and azacitidine in the treatment of TP53-mutated AML
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses some updates from a Phase I expansion study investigating the use of eprenetapopt (APR-246) plus venetoclax and azacitidine in the treatment of patients with TP53-mutated acute myeloid leukemia (AML). Dr Sallman highlights the response rates seen in patients treated with this triplet combination, including complete remission rate and safety. Dr Sallman then discusses some findings from a Phase II trial which investigated the use of eprenetapopt and azacitidine alone, and the future that novel combination therapies may have in a transplant setting and for subsets of patients with p53-mutant disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
